This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Societal CDMO Beheer

Beheer criteriumcontroles 2/4

De CEO Societal CDMO is J. Enloe, benoemd in Dec2020, heeft een ambtstermijn van 3.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.27M, bestaande uit 25.2% salaris en 74.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.76% van de aandelen van het bedrijf, ter waarde $ 881.75K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.5 jaar en 3.3 jaar.

Belangrijke informatie

J. Enloe

Algemeen directeur

US$2.3m

Totale compensatie

Percentage CEO-salaris	25.2%
Dienstverband CEO	3.3yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	2.5yrs
Gemiddelde ambtstermijn bestuur	3.3yrs

Recente managementupdates

Recent updates

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Feb 10

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Feb 02

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Apr 29

Is Recro Pharma (NASDAQ:REPH) A Risky Investment?

Jan 06

Recro Pharma jumps 15% on Q1 result estimates beat

May 07

Would Shareholders Who Purchased Recro Pharma's (NASDAQ:REPH) Stock Year Be Happy With The Share price Today?

Feb 15

Analyse CEO-vergoeding

Hoe is J. Enloe's beloning veranderd ten opzichte van Societal CDMO's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Dec 31 2023	n/a	n/a	-US$13m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$20m
Dec 31 2022	US$2m	US$572k	-US$20m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	-US$9m
Dec 31 2021	US$1m	US$550k	-US$11m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	n/a	n/a	-US$19m
Mar 31 2021	n/a	n/a	-US$27m
Dec 31 2020	US$1m	US$11k	-US$28m

Compensatie versus markt: De totale vergoeding ($USD 2.27M ) J. } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.00K ).

Compensatie versus inkomsten: De vergoeding van J. is gestegen terwijl het bedrijf verliesgevend is.

CEO

J. Enloe (59 yo)

3.3yrs

Tenure

US$2,271,540

Compensatie

Mr. J. David Enloe, Jr., serves as President, Chief Executive Officer and Director at Societal CDMO, Inc. (formerly known as Recro Pharma, Inc.) since December 16, 2020. Mr. Enloe had been the Chief Execut...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Wayne Weisman	Executive Chairman of the Board	16.3yrs	US$219.89k	0.22% $ 258.5k
J. Enloe	President	3.3yrs	US$2.27m	0.76% $ 881.8k
Ryan Lake	Senior VP & CFO	6.3yrs	US$1.42m	0.49% $ 575.0k
Marshall Rizzo	Senior VP & COO	1.9yrs	geen gegevens	geen gegevens
Richard Sidwell	Senior VP & Chief Scientific Officer	no data	geen gegevens	geen gegevens
Cristin Grove	Vice President of Sales	2.3yrs	geen gegevens	geen gegevens
Erica Raether	Senior VP & Chief People Officer	2.8yrs	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van SCTL wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Wayne Weisman	Executive Chairman of the Board	16.3yrs	US$219.89k	0.22% $ 258.5k
J. Enloe	President	3.3yrs	US$2.27m	0.76% $ 881.8k
Winston Churchill	Independent Director	16.3yrs	US$192.39k	0.22% $ 250.8k
Mathew Arens	Director	less than a year	geen gegevens	0.60% $ 698.5k
William Ashton	Independent Director	15.3yrs	US$194.89k	0.18% $ 209.0k
Laura Parks	Independent Director	2.8yrs	US$189.89k	0% $ 0
Bryan Reasons	Independent Director	7.1yrs	US$194.89k	0.21% $ 239.2k
James Miller	Independent Director	3.2yrs	US$192.39k	0.15% $ 169.3k
Elena Cant	Independent Director	1.6yrs	US$30.80k	0.028% $ 33.0k

3.3yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SCTL wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).

This company has been acquired

Societal CDMO Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

High number of new directors

High number of new directors

Societal Cdmo Announces Appointment of Matt Arens to Board of Directors

Societal CDMO, Inc. Appoints Elena Cant as Board of Directors

Societal CDMO, Inc., Annual General Meeting, May 18, 2022

Recent updates

Societal CDMO, Inc. Files Form 15

Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index

Societal CDMO's Common Stock to be Delisted from the Nasdaq Capital Market as a Result of the Merger with CoreRx

Full year 2023 earnings: EPS and revenues exceed analyst expectations

CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc. (NasdaqCM:SCTL) from First Light Asset Management, LLC and Others for approximately $120 million.

New major risk - Share price stability

Now 29% overvalued after recent price rise

Societal CDMO, Inc.'s (NASDAQ:SCTL) Price Is Right But Growth Is Lacking After Shares Rocket 38%

Is There An Opportunity With Societal CDMO, Inc.'s (NASDAQ:SCTL) 46% Undervaluation?

Is Societal CDMO (NASDAQ:SCTL) Weighed On By Its Debt Load?

Price target decreased by 14% to US$1.86

High number of new directors

Nasdaq Grants Societal CDMO an Additional 180 Calendar Days to Regain Compliance with Minimum Bid Price Requirement

Societal CDMO, Inc. Resets Earnings Guidance for the Year 2023

Societal CDMO, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Societal CDMO, Inc. Reduces its Workforce by 26 Positions Across All Aspects of the Business

High number of new directors

Price target decreased by 18% to US$2.30

Societal CDMO, Inc. has completed a Follow-on Equity Offering.

Societal Cdmo Announces Appointment of Matt Arens to Board of Directors

Consensus EPS estimates fall by 18%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS misses analyst expectations

Societal CDMO, Inc. to Report Q2, 2023 Results on Aug 09, 2023

New minor risk - Share price stability

Does Societal CDMO (NASDAQ:SCTL) Have A Healthy Balance Sheet?

Societal CDMO Receives Deficiency Letter from Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Societal CDMO, Inc. Reaffirms 2023 Financial Guidance

Societal CDMO, Inc. to Report Q1, 2023 Results on May 10, 2023

Forecast to breakeven in 2025

Price target decreased by 13% to US$3.64

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 19% to US$5.00

Consensus EPS estimates fall by 16%

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Societal CDMO, Inc. has completed a Follow-on Equity Offering in the amount of $30.625911 million.

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year 2022

Societal CDMO, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Societal CDMO signs two CDMO service agreements

Societal CDMO, Inc. Appoints Elena Cant as Board of Directors

Societal stock soars 20% on signing 2 manufacturing contracts

Societal CDMO estimates to receive up to $50M on real estates' sales

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Societal CDMO, Inc. Provides Earnings Guidance for the Full Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Societal CDMO, Lannett amend license and supply deal

Railroad Ranch Capital Engages in Discussions with Societal CDMO

Societal Cdmo Unveils 20/80 Second Source Technical Transfer Service Model, Offering Cost and Time Savings for Pharmaceutical Manufacturing

Consensus forecasts updated

Societal CDMO, Inc. Provides Earnings Guidance for the Year Ending December 31, 2022

Societal CDMO, Inc. to Report Q1, 2022 Results on May 11, 2022

These 4 Measures Indicate That Societal CDMO (NASDAQ:SCTL) Is Using Debt Extensively

Price target decreased to US$5.00

Societal CDMO, Inc., Annual General Meeting, May 18, 2022

Consensus forecasts updated

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Recro Pharma, Inc. Provides Earnings Guidance for the Year 2022

Recro Pharma, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Is Recro Pharma (NASDAQ:REPH) A Risky Investment?

Third quarter 2021 earnings released: US$0.068 loss per share (vs US$0.09 loss in 3Q 2020)

Consensus forecasts updated

Consensus forecasts updated

Recro Pharma, Inc. (NasdaqCM:REPH) acquired IRISYS, LLC from EPS Americas, Corp., IriSys, Inc. and Continent Pharmaceuticals U.S., Inc. for $51.7 million.

Second quarter 2021 earnings released: EPS US$0.032 (vs US$0.26 loss in 2Q 2020)

Recro Pharma, Inc.(NasdaqCM:REPH) dropped from Russell 3000E Growth Index

Recro Pharma, Inc. Expands Capabilities for Growing Clinical Trial Services Offerings

Recro Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $29.999999 million.